Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02696031




Registration number
NCT02696031
Ethics application status
Date submitted
13/10/2015
Date registered
2/03/2016
Date last updated
29/04/2022

Titles & IDs
Public title
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
Scientific title
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Secondary ID [1] 0 0
CAIN457H2315
Universal Trial Number (UTN)
Trial acronym
PREVENT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-radiographic Spondyloarthritis 0 0
Condition category
Condition code
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis
Musculoskeletal 0 0 0 0
Osteoarthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Secukinumab
Treatment: Drugs - Placebo

Experimental: Secukinumab, 150 mg Load (Core phase) - Secukinumab 150 mg s.c., pre-filled syringe (PFS) at baseline, Weeks 1, 2, and 3, followed by administration every four weeks starting at Week 4, Load, Core phase

Experimental: Secukinumab, 150 mg No Load (Core phase) - Secukinumab 150 mg s.c. PFS at baseline, placebo at Weeks 1, 2, and 3, followed by secukinumab 150 mg PFS administration every four weeks starting at Week 4, No Load, Core phase

Placebo comparator: Placebo (Core phase) - Placebo s.c., PFS at baseline, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4, Core phase

Experimental: Core Phase Responder 150 mg (Extension phase) - Core Phase Responder 150 mg blinded: secukinumab 150 mg s.c. PFS and placebo (1 mL) s.c. PFS every four weeks, in the Extension phase

Experimental: Core Phase Responder 300 mg (Extension phase) - Core Phase Responder 300 mg blinded: 2 injections with secukinumab 150 mg s.c. PFS every four weeks, in the Extension phase

Experimental: Core Phase Non-Responder 300 mg (Extension phase) - Core Phase Non-Responder 300 mg: 2 injections with secukinumab 150 mg s.c. PFS every four weeks open-label, in the Extension phase


Treatment: Drugs: Secukinumab
Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly

Treatment: Drugs: Placebo
Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
The Number and Percentage of TNF Naive Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 40 Response at Week 16
Timepoint [1] 0 0
Week 16
Primary outcome [2] 0 0
The Number and Percentage of TNF Naive Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 52
Timepoint [2] 0 0
Week 52
Secondary outcome [1] 0 0
The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 40 Response
Timepoint [1] 0 0
Week 16 and week 52
Secondary outcome [2] 0 0
The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 20 Response
Timepoint [2] 0 0
Week 16
Secondary outcome [3] 0 0
The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response
Timepoint [3] 0 0
Week 16
Secondary outcome [4] 0 0
The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society Partial Remission (ASAS PR)
Timepoint [4] 0 0
Week 16
Secondary outcome [5] 0 0
Change in Bath Ankylosing Spondylitis Functional Index (BASFI)
Timepoint [5] 0 0
Baseline and Week 16
Secondary outcome [6] 0 0
The Number and Percentage of Patients to Achieve a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response
Timepoint [6] 0 0
Week 16 and 52
Secondary outcome [7] 0 0
Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Timepoint [7] 0 0
Baseline and Week 16
Secondary outcome [8] 0 0
Change in Ankylosing Spondylitis Quality of Life (ASQoL) Scores at Week 16
Timepoint [8] 0 0
Baseline and Week 16
Secondary outcome [9] 0 0
Change in Ankylosing Spondylitis Quality of Life (ASQoL) Scores at Week 52
Timepoint [9] 0 0
Baseline and Week 52
Secondary outcome [10] 0 0
The Number and Percentage of Patients Who Achieved an Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-Reactive Protein (CRP) Inactive Disease
Timepoint [10] 0 0
Week 52
Secondary outcome [11] 0 0
Change in High Sensitivity C-reactive Protein
Timepoint [11] 0 0
Baseline and Week 16
Secondary outcome [12] 0 0
Change in Short Form-36 Physical Component Summary (SF-36 PCS)
Timepoint [12] 0 0
Baseline and Week 16
Secondary outcome [13] 0 0
Change in Sacroiliac Joint Edema - Week 16
Timepoint [13] 0 0
Baseline and Week 16
Secondary outcome [14] 0 0
Change in Sacroiliac Joint Edema - Week 52
Timepoint [14] 0 0
Baseline and Week 52

Eligibility
Key inclusion criteria
* Male or non-pregnant, non-nursing female patients at least 18 years of age
* Diagnosis of axial spondyloarthritis according to Ankylosing SpondyloArthritis International Society (ASAS) axial spondyloarthritis criteria
* objective signs of inflammation (magnetic resonance imaging (MRI) or abnormal C-reactive protein)
* active axial spondyloarthritis as assessed by total Bath Ankylosing Spondylitis Disease Activity Index >=4 cm
* Spinal pain as measured by Bath Ankylosing Spondylitis Disease Activity Index question #2 = 4 cm (0-10 cm) at baseline
* Total back pain as measured by Visual Analogue scale = 40 mm (0-100 mm) at baseline
* Patients should have been on at least 2 different non-steroidal anti-inflammatory drugs with an inadequate response
* Patients who have been on a Tumor Necrosis Factor (TNF) a inhibitor (not more than one) must have experienced an inadequate response
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Patients with radiographic evidence for sacroiliitis, grade = 2 bilaterally or grade = 3 unilaterally
* Inability or unwillingness to undergo MRI
* Chest X-ray or MRI with evidence of ongoing infectious or malignant process
* Patients taking high potency opioid analgesics
* Previous exposure to secukinumab or any other biologic drug directly targeting interleukin-17 (IL-17) or IL-17 receptor
* Pregnant or nursing (lactating) women

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
29/04/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
11/03/2021
Sample size
Target
Accrual to date
Final
555
Recruitment in Australia
Recruitment state(s)
NSW,QLD,TAS,VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - Coffs Harbour
Recruitment hospital [2] 0 0
Novartis Investigative Site - Maroochydore
Recruitment hospital [3] 0 0
Novartis Investigative Site - Hobart
Recruitment hospital [4] 0 0
Novartis Investigative Site - Malvern East
Recruitment hospital [5] 0 0
Novartis Investigative Site - Woolloongabba
Recruitment postcode(s) [1] 0 0
2450 - Coffs Harbour
Recruitment postcode(s) [2] 0 0
4558 - Maroochydore
Recruitment postcode(s) [3] 0 0
7000 - Hobart
Recruitment postcode(s) [4] 0 0
3145 - Malvern East
Recruitment postcode(s) [5] 0 0
QLD 4102 - Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Idaho
Country [6] 0 0
United States of America
State/province [6] 0 0
Kentucky
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Montana
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
North Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
Oklahoma
Country [12] 0 0
United States of America
State/province [12] 0 0
Oregon
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
South Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
Austria
State/province [16] 0 0
Graz
Country [17] 0 0
Austria
State/province [17] 0 0
Vienna
Country [18] 0 0
Belgium
State/province [18] 0 0
Bruxelles
Country [19] 0 0
Belgium
State/province [19] 0 0
Genk
Country [20] 0 0
Belgium
State/province [20] 0 0
Gent
Country [21] 0 0
Bulgaria
State/province [21] 0 0
Pleven
Country [22] 0 0
Bulgaria
State/province [22] 0 0
Sofia
Country [23] 0 0
Czechia
State/province [23] 0 0
Czech Republic
Country [24] 0 0
Czechia
State/province [24] 0 0
CZE
Country [25] 0 0
Czechia
State/province [25] 0 0
CZ
Country [26] 0 0
Czechia
State/province [26] 0 0
Uherske Hradiste
Country [27] 0 0
France
State/province [27] 0 0
Haute Vienne
Country [28] 0 0
France
State/province [28] 0 0
Bordeaux Cedex
Country [29] 0 0
France
State/province [29] 0 0
Boulogne Billancourt
Country [30] 0 0
France
State/province [30] 0 0
Chambray les Tours
Country [31] 0 0
France
State/province [31] 0 0
Monaco
Country [32] 0 0
France
State/province [32] 0 0
Paris Cedex 14
Country [33] 0 0
France
State/province [33] 0 0
Poitiers
Country [34] 0 0
France
State/province [34] 0 0
Rouen Cedex
Country [35] 0 0
Germany
State/province [35] 0 0
Niedersachsen
Country [36] 0 0
Germany
State/province [36] 0 0
Berlin
Country [37] 0 0
Germany
State/province [37] 0 0
Cottbus
Country [38] 0 0
Germany
State/province [38] 0 0
Dresden
Country [39] 0 0
Germany
State/province [39] 0 0
Erlangen
Country [40] 0 0
Germany
State/province [40] 0 0
Freiburg
Country [41] 0 0
Germany
State/province [41] 0 0
Hamburg
Country [42] 0 0
Germany
State/province [42] 0 0
Herne
Country [43] 0 0
Germany
State/province [43] 0 0
Magdeburg
Country [44] 0 0
Germany
State/province [44] 0 0
Potsdam
Country [45] 0 0
Hungary
State/province [45] 0 0
Budapest
Country [46] 0 0
Hungary
State/province [46] 0 0
Debrecen
Country [47] 0 0
Hungary
State/province [47] 0 0
Eger
Country [48] 0 0
Hungary
State/province [48] 0 0
Szeged
Country [49] 0 0
Hungary
State/province [49] 0 0
Szekesfehervar
Country [50] 0 0
Hungary
State/province [50] 0 0
Veszprem
Country [51] 0 0
Israel
State/province [51] 0 0
Haifa
Country [52] 0 0
Israel
State/province [52] 0 0
Kfar Saba
Country [53] 0 0
Israel
State/province [53] 0 0
Ramat Gan
Country [54] 0 0
Israel
State/province [54] 0 0
Tel Aviv
Country [55] 0 0
Italy
State/province [55] 0 0
VR
Country [56] 0 0
Italy
State/province [56] 0 0
Bologna
Country [57] 0 0
Italy
State/province [57] 0 0
Novara
Country [58] 0 0
Italy
State/province [58] 0 0
Padova
Country [59] 0 0
Italy
State/province [59] 0 0
Pisa
Country [60] 0 0
Japan
State/province [60] 0 0
Kagawa
Country [61] 0 0
Japan
State/province [61] 0 0
Osaka
Country [62] 0 0
Japan
State/province [62] 0 0
Tokyo
Country [63] 0 0
Korea, Republic of
State/province [63] 0 0
Seoul
Country [64] 0 0
Mexico
State/province [64] 0 0
Coahuila
Country [65] 0 0
Mexico
State/province [65] 0 0
Estado De Mexico
Country [66] 0 0
Mexico
State/province [66] 0 0
Jalisco
Country [67] 0 0
Mexico
State/province [67] 0 0
MEX
Country [68] 0 0
Netherlands
State/province [68] 0 0
Amsterdam
Country [69] 0 0
Netherlands
State/province [69] 0 0
Groningen
Country [70] 0 0
Netherlands
State/province [70] 0 0
Maastricht
Country [71] 0 0
Norway
State/province [71] 0 0
Kongsvinger
Country [72] 0 0
Norway
State/province [72] 0 0
Moss
Country [73] 0 0
Poland
State/province [73] 0 0
Krakow
Country [74] 0 0
Poland
State/province [74] 0 0
Poznan
Country [75] 0 0
Poland
State/province [75] 0 0
Warszawa
Country [76] 0 0
Poland
State/province [76] 0 0
Wroclaw
Country [77] 0 0
Portugal
State/province [77] 0 0
Almada
Country [78] 0 0
Portugal
State/province [78] 0 0
Braga
Country [79] 0 0
Portugal
State/province [79] 0 0
Lisboa
Country [80] 0 0
Portugal
State/province [80] 0 0
Ponte de Lima
Country [81] 0 0
Russian Federation
State/province [81] 0 0
Barnaul
Country [82] 0 0
Russian Federation
State/province [82] 0 0
Ekaterinburg
Country [83] 0 0
Russian Federation
State/province [83] 0 0
Kemerovo
Country [84] 0 0
Russian Federation
State/province [84] 0 0
Moscow
Country [85] 0 0
Russian Federation
State/province [85] 0 0
Saint Petersburg
Country [86] 0 0
Russian Federation
State/province [86] 0 0
Saratov
Country [87] 0 0
Russian Federation
State/province [87] 0 0
Smolensk
Country [88] 0 0
Spain
State/province [88] 0 0
Alicante
Country [89] 0 0
Spain
State/province [89] 0 0
Andalucia
Country [90] 0 0
Spain
State/province [90] 0 0
Barcelona
Country [91] 0 0
Spain
State/province [91] 0 0
Cantabria
Country [92] 0 0
Spain
State/province [92] 0 0
Comunidad Valenciana
Country [93] 0 0
Spain
State/province [93] 0 0
Galicia
Country [94] 0 0
Spain
State/province [94] 0 0
Pais Vasco
Country [95] 0 0
Spain
State/province [95] 0 0
Pontevedra
Country [96] 0 0
Spain
State/province [96] 0 0
Madrid
Country [97] 0 0
Sweden
State/province [97] 0 0
Goteborg
Country [98] 0 0
Sweden
State/province [98] 0 0
Lund
Country [99] 0 0
Sweden
State/province [99] 0 0
Uppsala
Country [100] 0 0
Switzerland
State/province [100] 0 0
Basel
Country [101] 0 0
Switzerland
State/province [101] 0 0
Fribourg
Country [102] 0 0
Turkey
State/province [102] 0 0
Ankara
Country [103] 0 0
United Kingdom
State/province [103] 0 0
Essex
Country [104] 0 0
United Kingdom
State/province [104] 0 0
London
Country [105] 0 0
United Kingdom
State/province [105] 0 0
Staffordshire
Country [106] 0 0
United Kingdom
State/province [106] 0 0
West Sussex
Country [107] 0 0
United Kingdom
State/province [107] 0 0
Bath
Country [108] 0 0
United Kingdom
State/province [108] 0 0
Doncaster
Country [109] 0 0
United Kingdom
State/province [109] 0 0
Middlesbrough
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Northampton
Country [111] 0 0
United Kingdom
State/province [111] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study was to demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to placebo in patients with nr-axSpA at Week 16 as well as Week 52 and long term efficacy and safety up to Week 104 (core phase) followed by an optional extension phase consisting of a 16-week randomized dose escalation treatment period and a continuous treatment period for up to Week 208
Trial website
https://clinicaltrials.gov/study/NCT02696031
Trial related presentations / publications
Merola JF, McInnes IB, Deodhar AA, Dey AK, Adamstein NH, Quebe-Fehling E, Aassi M, Peine M, Mehta NN. Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications. Rheumatol Ther. 2022 Jun;9(3):935-955. doi: 10.1007/s40744-022-00434-z. Epub 2022 Mar 19.
Braun J, Blanco R, Marzo-Ortega H, Gensler LS, van den Bosch F, Hall S, Kameda H, Poddubnyy D, van de Sande M, Wiksten AS, Porter BO, Shete A, Richards HB, Haemmerle S, Deodhar A. Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT. Arthritis Res Ther. 2021 Sep 4;23(1):231. doi: 10.1186/s13075-021-02613-9.
Deodhar A, Blanco R, Dokoupilova E, Hall S, Kameda H, Kivitz AJ, Poddubnyy D, van de Sande M, Wiksten AS, Porter BO, Richards HB, Haemmerle S, Braun J. Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study. Arthritis Rheumatol. 2021 Jan;73(1):110-120. doi: 10.1002/art.41477. Epub 2020 Nov 24.
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02696031